"A phase  study of children ages  years with attention deficithyperactivity disorder ADHD has shown that a delayedrelease longacting formulation of the stimulant methylphenidate when taken in the evening led to significant improvement in ADHD symptoms and functional impairment first thing the next morning compared to a placebo. Children taking the delayedrelease stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening according to the study results published in Journal of Child and Adolescent Psychopharmacology a peerreviewed journal from Mary Ann Liebert Inc. publishers. The article is available free on the Journal of Child and Adolescent Psychopharmacology website.  The article entitled Efficacy and Safety of HLD DelayedRelease and ExtendedRelease Methylphenidate in Children with AttentionDeficitHyperactivity Disorder httponline.liebertpub.comdoifull.cap.. is coauthored by Steven Pliszka MD from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital Boston MA Westside Medical Family Practice Clinton UT University of Tennessee Health Science Center Memphis TN Meridien Research Maitland and Bradenton FL Childrens Development Center Winter Park FL Ironshore Pharmaceuticals  Development Grand Cayman Cayman Islands and Mount Sinai Medical Center New York NY on behalf of the HLD Study Group.  The drug formulation which consists of two layers of microbeads with an inner drugloaded core delays release of the active ingredient for  hours and then provides controlled extended release designed to cover the early morning into the evening. The medication was well tolerated with the main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.  Developing new formulations of effective medications for patients with ADHD improves the lives of children with the disorder says Harold S. Koplewicz MD EditorinChief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.  About the Journal  Journal of Child and Adolescent Psychopharmacology is an authoritative peerreviewed journal published bimonthly in print and online. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website http  About the Publisher  Mary Ann Liebert Inc. publishers is a privately held fully integrated media company known for establishing authoritative peerreviewed journals in many promising areas of science and biomedical research including Cyberpsychology Behavior and Social Networking Games for Health Journal and Violence and Gender. Its biotechnology trade magazine GEN Genetic Engineering  Biotechnology News was the first in its field and is today the industrys most widely read publication worldwide. A complete list of the firms  journals books and newsmagazines is available on the Mary Ann Liebert Inc. publishers website http"